These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 27899263)

  • 81. Sex Is Associated with Adalimumab Side Effects and Drug Survival in Patients with Crohn's Disease.
    Lie MR; Kreijne JE; van der Woude CJ
    Inflamm Bowel Dis; 2017 Jan; 23(1):75-81. PubMed ID: 28002127
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Adalimumab Monotherapy and a Combination with Azathioprine for Crohn's Disease: A Prospective, Randomized Trial.
    Matsumoto T; Motoya S; Watanabe K; Hisamatsu T; Nakase H; Yoshimura N; Ishida T; Kato S; Nakagawa T; Esaki M; Nagahori M; Matsui T; Naito Y; Kanai T; Suzuki Y; Nojima M; Watanabe M; Hibi T;
    J Crohns Colitis; 2016 Nov; 10(11):1259-1266. PubMed ID: 27566367
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Growth Improvement with Adalimumab Treatment in Children with Moderately to Severely Active Crohn's Disease.
    Walters TD; Faubion WA; Griffiths AM; Baldassano RN; Escher J; Ruemmele FM; Hyams JS; Lazar A; Eichner S; Huang B; Li Y; Thakkar RB
    Inflamm Bowel Dis; 2017 Jun; 23(6):967-975. PubMed ID: 28301428
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Clinical experience with adalimumab in a multicenter Swiss cohort of patients with Crohn's disease.
    Nichita C; Stelle M; Vavricka S; El-Wafa Ali A; Ballabeni P; de Saussure P; Straumann A; Rogler G; Michetti P
    Digestion; 2010; 81(2):78-85. PubMed ID: 20093835
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Long-term durability of infliximab treatment in Crohn's disease and efficacy of dose "escalation" in patients losing response.
    Chaparro M; Panes J; García V; Mañosa M; Esteve M; Merino O; Andreu M; Gutierrez A; Gomollón F; Cabriada JL; Montoro MA; Mendoza JL; Nos P; Gisbert JP
    J Clin Gastroenterol; 2011 Feb; 45(2):113-8. PubMed ID: 21242747
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease.
    Loftus EV; Johnson SJ; Yu AP; Wu EQ; Chao J; Mulani PM
    Eur J Gastroenterol Hepatol; 2009 Nov; 21(11):1302-9. PubMed ID: 19465858
    [TBL] [Abstract][Full Text] [Related]  

  • 87. The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy.
    Lichtiger S; Binion DG; Wolf DC; Present DH; Bensimon AG; Wu E; Yu AP; Cardoso AT; Chao J; Mulani PM; Lomax KG; Kent JD
    Aliment Pharmacol Ther; 2010 Nov; 32(10):1228-39. PubMed ID: 20955442
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Similar response to adalimumab in patients with active Crohn's disease either naive to biologic agents or with prior loss of response or intolerance to infliximab.
    Triantafillidis JK; Mantzaris G; Karagiannis J; Papavasilliou E; Papatheodoridis G; Fouskas J; Malgarinos G; Gikas A; Papamichael K; Mathou N; Symboulakis E; Karamanolis D
    Rev Med Chir Soc Med Nat Iasi; 2010; 114(1):85-90. PubMed ID: 20509281
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Clinical efficacy of adalimumab in Crohn's disease: a real practice observational study in Japan.
    Takeshima F; Yoshikawa D; Higashi S; Morisaki T; Oda H; Ikeda M; Machida H; Matsushima K; Minami H; Akazawa Y; Yamaguchi N; Ohnita K; Isomoto H; Ueno M; Nakao K
    BMC Gastroenterol; 2016 Jul; 16(1):82. PubMed ID: 27472988
    [TBL] [Abstract][Full Text] [Related]  

  • 90. The safety and efficacy of adalimumab in patients with Crohn's disease: the experience of a single Canadian tertiary care centre.
    Teriaky A; Gregor J; Yan B; Ponich T; Chande N; Mosli M
    Scand J Gastroenterol; 2014 Mar; 49(3):280-6. PubMed ID: 24329040
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI).
    Dewint P; Hansen BE; Verhey E; Oldenburg B; Hommes DW; Pierik M; Ponsioen CI; van Dullemen HM; Russel M; van Bodegraven AA; van der Woude CJ
    Gut; 2014 Feb; 63(2):292-9. PubMed ID: 23525574
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn's Disease.
    Horneff G; Seyger MMB; Arikan D; Kalabic J; Anderson JK; Lazar A; Williams DA; Wang C; Tarzynski-Potempa R; Hyams JS
    J Pediatr; 2018 Oct; 201():166-175.e3. PubMed ID: 30054164
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Higher Adalimumab Drug Levels are Associated with Mucosal Healing in Patients with Crohn's Disease.
    Zittan E; Kabakchiev B; Milgrom R; Nguyen GC; Croitoru K; Steinhart AH; Silverberg MS
    J Crohns Colitis; 2016 May; 10(5):510-5. PubMed ID: 26783345
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Successful treatment of oral Crohn's disease by anti-TNF-alpha dose escalation - a case report.
    Bokemeyer A; Tentrop N; Barth PJ; Lenze F; Hengst K; Kleinheinz J; Bettenworth D
    BMC Gastroenterol; 2018 Jun; 18(1):88. PubMed ID: 29914414
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Association of Early Postinduction Adalimumab Exposure With Subsequent Clinical and Biomarker Remission in Children with Crohn's Disease.
    Rinawi F; Ricciuto A; Church PC; Frost K; Crowley E; Walters TD; Griffiths AM
    Inflamm Bowel Dis; 2021 Jun; 27(7):1079-1087. PubMed ID: 32978946
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Safety of Adalimumab and Predictors of Adverse Events in 1693 Japanese Patients with Crohn's Disease.
    Ogata H; Watanabe M; Matsui T; Hase H; Okayasu M; Tsuchiya T; Shinmura Y; Hibi T
    J Crohns Colitis; 2016 Sep; 10(9):1033-41. PubMed ID: 26961546
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Results of a retrospective study on the efficacy and safety of adalimumab 80 mg administrated every other week in patients with psoriasis at a single Japanese institution.
    Kamiya K; Karakawa M; Komine M; Kishimoto M; Sugai J; Ohtsuki M
    J Dermatol; 2019 Mar; 46(3):199-205. PubMed ID: 30672612
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Editorial: adalimumab dose escalation is effective for managing secondary loss of response in Crohn's disease.
    Moss AC
    Aliment Pharmacol Ther; 2014 Nov; 40(10):1249. PubMed ID: 25303382
    [No Abstract]   [Full Text] [Related]  

  • 99. Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial.
    Hinojosa J; Gomollón F; García S; Bastida G; Cabriada JL; Saro C; Ceballos D; Peñate M; Gassull MA;
    Aliment Pharmacol Ther; 2007 Feb; 25(4):409-18. PubMed ID: 17269996
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis.
    Kaplan GG; Hur C; Korzenik J; Sands BE
    Aliment Pharmacol Ther; 2007 Dec; 26(11-12):1509-20. PubMed ID: 17931345
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.